AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1695778 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 320830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipamperone (80 mg daily)
Number of subjects: 40
Study 320830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 320830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipamperone
Number of subjects: 40
Study 7151088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min infusion for 15 min)
Number of subjects: 19
Study 7151088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tiapamil (1.5 mg/kg loading dose followed by 75 micrograms/kg/min infusion for 15 min)
Number of subjects: 19
Study 30614524 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV self-testing
Number of subjects: 397
Study 29360600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nitrate low-thiocyanate smoothie (∼4 mmol nitrate, ∼5 μmol thiocyanate)
Number of subjects: 11
Study 29360600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nitrate high-thiocyanate smoothie (∼4 mmol nitrate, ∼72 μmol thiocyanate)
Number of subjects: 11
Study 29360600 — intervention group
Group type: COMPARATOR
Intervention: Low-nitrate low-thiocyanate smoothie (∼0.3 mmol nitrate, ∼5 μmol thiocyanate)
Number of subjects: 11
Study 29360600 — intervention group
Group type: COMPARATOR
Intervention: Low-nitrate high-thiocyanate smoothie (∼0.3 mmol nitrate, ∼72 μmol thiocyanate)
Number of subjects: 11
Study 27102891 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes before a meal
Number of subjects: 18
Study 27102891 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic enzyme replacement therapy (PERT) administered 10 minutes after a meal
Number of subjects: 18
Study 27102891 — intervention group
Group type: EXPERIMENTAL
Intervention: PERT timing changed from after to before meal
Number of subjects: 18
Study 27102891 — intervention group
Group type: COMPARATOR
Intervention: PERT taken after the meal
Number of subjects: 18
Study 24471786 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 1386
Study 24471786 — intervention group
Group type: COMPARATOR
Intervention: No Dexamethasone (Control)
Number of subjects: 1386
Study 24471786 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 1386
Study 24471786 — intervention group
Group type: COMPARATOR
Intervention: Non-Smokers (Control)
Number of subjects: 1386
Study 24471786 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Abusers
Number of subjects: 1386
Study 24471786 — intervention group
Group type: COMPARATOR
Intervention: Non-Alcohol Abusers (Control)
Number of subjects: 1386
Study 22260713 — intervention group
Group type: EXPERIMENTAL
Intervention: Running therapy (RT) or Nordic walking (NW) in addition to usual care, group-based, 1 hour session, two times a week for 6 months, increasing intensity.
Number of subjects: 0
Study 22260713 — intervention group
Group type: COMPARATOR
Intervention: Low intensive non-aerobic exercises (Control group).
Number of subjects: 0
Study 22260713 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 0
Study 19900312 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination
Number of subjects: 0
Study 19900312 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 17983307 — intervention group
Group type: EXPERIMENTAL
Intervention: Made-in-the-U.S. scenario condition; European Americans
Number of subjects: 0
Study 17983307 — intervention group
Group type: EXPERIMENTAL
Intervention: Made-in-Japan scenario condition; European Americans
Number of subjects: 0
Study 17983307 — intervention group
Group type: EXPERIMENTAL
Intervention: Value orientation mediation; Study 2
Number of subjects: 0
Study 17983307 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily event sampling study; Study 3
Number of subjects: 0
Study 17983307 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional events congruent with personal values
Number of subjects: 0
Study 15660541 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled intervention
Number of subjects: 9
Study 11930154 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright fearful faces
Number of subjects: 0
Study 11930154 — intervention group
Group type: COMPARATOR
Intervention: Inverted faces
Number of subjects: 0
Study 11930154 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-specific N170 component
Number of subjects: 0
Study 9817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (six cycles of cyclophosphamide, methotrexate, fluorouracil, and prednisone)
Number of subjects: 0
Study 9817265 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (observation group)
Number of subjects: 0
Study 9817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (for patients with large tumors, both ER+ and ER-)
Number of subjects: 0
Study 9817265 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (observation group for patients with large tumors, both ER+ and ER-)
Number of subjects: 0
Study 9817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk patients (ER+ tumors < 3 cm) monitored without therapy
Number of subjects: 0
Study 9817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal patients
Number of subjects: 0
Study 9817265 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal patients
Number of subjects: 0
Study 7659764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum during week 1 post-cessation
Number of subjects: 215
Study 2664631 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 12 interrupted 10‐0 sutures with a single running 11‐0 suture (IR)
Number of subjects: 120
Study 2664631 — intervention group
Group type: COMPARATOR
Intervention: Double running 10‐0 and 11‐0 sutures (DR)
Number of subjects: 120
Study 765528 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaproterenol syrup
Number of subjects: 50
Study 765528 — intervention group
Group type: COMPARATOR
Intervention: Placebo syrup
Number of subjects: 50
Study 30421863 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIFAST program (OP)
Number of subjects: 273
Study 30421863 — intervention group
Group type: COMPARATOR
Intervention: Food-based dietary plan (FB)
Number of subjects: 273
Study 27918661 — intervention group
Group type: EXPERIMENTAL
Intervention: Power nap
Number of subjects: 34
Study 27918661 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic breathing
Number of subjects: 34
Study 27918661 — intervention group
Group type: COMPARATOR
Intervention: Disturbed conditions
Number of subjects: 34
Study 27918661 — intervention group
Group type: COMPARATOR
Intervention: Nondisturbed conditions
Number of subjects: 34
Study 25452437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (150 minutes per week of aerobic exercise and supervised strength training twice per week)
Number of subjects: 121
Study 25452437 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121
Study 25452437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 121
Study 22795715 — intervention group
Group type: EXPERIMENTAL
Intervention: Microplegia (Mic)
Number of subjects: 80
Study 21585704 — intervention group
Group type: EXPERIMENTAL
Intervention: BevCG (bevacizumab plus cisplatin-gemcitabine)
Number of subjects: 0
Study 21585704 — intervention group
Group type: COMPARATOR
Intervention: CP (cisplatin plus pemetrexed)
Number of subjects: 0
Study 19854376 — intervention group
Group type: EXPERIMENTAL
Intervention: Soymilk (3 servings of vanilla soy per day for 4 weeks)
Number of subjects: 31
Study 19854376 — intervention group
Group type: COMPARATOR
Intervention: Reduced fat dairy (3 servings per day for 4 weeks)
Number of subjects: 31
Study 16711170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid-based adhesive dressings
Number of subjects: 45
Study 16711170 — intervention group
Group type: COMPARATOR
Intervention: Polyurethane adhesive dressing
Number of subjects: 45
Study 16711170 — intervention group
Group type: COMPARATOR
Intervention: Soft silicone adhesive dressing
Number of subjects: 45
Study 14764775 — intervention group
Group type: COMPARATOR
Intervention: 100 microg octreotide
Number of subjects: 12
Study 14764775 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg SOM230
Number of subjects: 12
Study 14764775 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg SOM230
Number of subjects: 12
Study 14764775 — intervention group
Group type: COMPARATOR
Intervention: octreotide
Number of subjects: 12
Study 14764775 — intervention group
Group type: EXPERIMENTAL
Intervention: SOM230
Number of subjects: 12
Study 11848115 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular intervention (ATVV) administered for 15 minutes, twice daily, 5 days per week, from 33 weeks of age until discharge.
Number of subjects: 37
Study 11848115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study 11848115 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory, tactile, visual, and vestibular intervention (ATVV)
Number of subjects: 37
Study 9666367 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions (classroom only, parent-child)
Number of subjects: 407
Study 9666367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 407
Study 8597883 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin, diclofenac, and naproxen (nonsteroidal anti-inflammatory drugs)
Number of subjects: 24
Study 8597883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2693074 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline 75 mg
Number of subjects: 1141
Study 2693074 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline 37.5 mg (1/2 tablet)
Number of subjects: 1141
Study 2693074 — intervention group
Group type: COMPARATOR
Intervention: placebo 1 tablet
Number of subjects: 1141
Study 2693074 — intervention group
Group type: COMPARATOR
Intervention: placebo 37.5 mg (1/2 tablet)
Number of subjects: 1141
Study 352195 — intervention group
Group type: EXPERIMENTAL
Intervention: RO 21‐3981 0.15 mg/kg
Number of subjects: 75
Study 352195 — intervention group
Group type: COMPARATOR
Intervention: diazepam
Number of subjects: 75
Study 352195 — intervention group
Group type: COMPARATOR
Intervention: thiopental
Number of subjects: 75
Study 30885233 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients (defined as ≥8 points on the Hospital Anxiety and Depression Scale)
Number of subjects: 292
Study 30885233 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed patients
Number of subjects: 292
Study 30885233 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of antidepressants
Number of subjects: 292
Study 30885233 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-cholesterol levels (per mmol/l)
Number of subjects: 292
Study 30885233 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity in women
Number of subjects: 292
Study 30885233 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-cholesterol levels
Number of subjects: 292
Study 27768515 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib (3 doses at 2-3-4 months)
Number of subjects: 984
Study 27768515 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib (3 doses at 3-4-5 months)
Number of subjects: 984
Study 27768515 — intervention group
Group type: COMPARATOR
Intervention: Control group (DTPa/Hib and IPV vaccination at 2-3-4 months)
Number of subjects: 984
Study 27768515 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib (3 doses)
Number of subjects: 984
Study 27768515 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-IPV/Hib (Group A)
Number of subjects: 984
Study 26747218 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-valve-mask + nasal cannula at 10 L/min
Number of subjects: 60
Study 26747218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrebreather face mask + nasal cannula at 10 L/min
Number of subjects: 60
Study 26747218 — intervention group
Group type: COMPARATOR
Intervention: Bag-valve-mask alone
Number of subjects: 60
Study 26747218 — intervention group
Group type: COMPARATOR
Intervention: Nonrebreather face mask alone
Number of subjects: 60
Study 24934646 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Change plus Dental Care (LCDC) program
Number of subjects: 132
Study 24934646 — intervention group
Group type: COMPARATOR
Intervention: Routine program (Control)
Number of subjects: 132
Study 23156974 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (2 mg/kg)
Number of subjects: 9
Study 23156974 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.05 mg/kg)
Number of subjects: 9
Study 23156974 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 9
Study 19528136 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8028
Study 19528136 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8028
Study 19528136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (2 years of one agent followed by 3 years of the other)
Number of subjects: 8028
Study 17340069 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobe-Mugos E (proteolytic enzymes) comprising papain 100 mg, trypsin 40 mg, and chymotrypsin 40 mg
Number of subjects: 69
Study 17340069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) low-dose isradipine (15 mg)
Number of subjects: 18
Study 15206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release (SR) high-dose isradipine (30 mg)
Number of subjects: 18
Study 15206666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 15206666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cocaine HCl (0.325 mg/kg)
Number of subjects: 18
Study 15206666 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cocaine HCl (0.650 mg/kg)
Number of subjects: 18
Study 11409597 — intervention group
Group type: EXPERIMENTAL
Intervention: Antistatic measures to reduce static electric fields in visual display units
Number of subjects: 120
Study 11409597 — intervention group
Group type: COMPARATOR
Intervention: Control group working with visual display units without antistatic measures
Number of subjects: 120
Study 11409597 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with office dust concentration >58 microg/m3
Number of subjects: 120
Study 11409597 — intervention group
Group type: COMPARATOR
Intervention: Control group with office dust concentration >58 microg/m3
Number of subjects: 120
Study 9207592 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 24
Study 9207592 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal ovarian cycles)
Number of subjects: 24
Study 9207592 — intervention group
Group type: EXPERIMENTAL
Intervention: POF without HRT
Number of subjects: 24
Study 7963223 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized‐free tests (Titmus, Reindeer, Butterfly, Figures)
Number of subjects: 34
Study 7963223 — intervention group
Group type: COMPARATOR
Intervention: Polarized tests (Titmus, Reindeer, Butterfly, Figures)
Number of subjects: 34
Study 3117399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential instillation of mitomycin C (MMC) and adriamycin (ADM); 20 mg MMC on day 1 and 40 mg ADM on day 2, repeated weekly for 5 weeks.
Number of subjects: 84
Study 3117399 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent instillation of MMC
Number of subjects: 84
Study 3117399 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) medication
Number of subjects: 84
Study 28739443 — intervention group
Group type: EXPERIMENTAL
Intervention: HAsauna (sauna exposure at 50°C, 30% RH)
Number of subjects: 9
Study 28739443 — intervention group
Group type: COMPARATOR
Intervention: HAtemp (temperate environment at 20°C, 40% RH)
Number of subjects: 9
Study 28739443 — intervention group
Group type: EXPERIMENTAL
Intervention: HAsauna
Number of subjects: 9
Study 28739443 — intervention group
Group type: COMPARATOR
Intervention: HAtemp
Number of subjects: 9
Study 28739443 — intervention group
Group type: EXPERIMENTAL
Intervention: HAsauna and HAtemp
Number of subjects: 9
Study 26347218 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (ALA) treatment (600mg once daily)
Number of subjects: 48
Study 26347218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24978844 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 353
Study 24978844 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education (WHE)
Number of subjects: 353
Study 22822623 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa capsules (500 +/- 10 mg per capsule, 2 g per day for 4 weeks)
Number of subjects: 88
Study 22822623 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 88
Study 20727129 — intervention group
Group type: EXPERIMENTAL
Intervention: Melaleuca oil and lavender oil (TTO/LO)
Number of subjects: 123
Study 20727129 — intervention group
Group type: EXPERIMENTAL
Intervention: Head lice 'suffocation' product
Number of subjects: 123
Study 20727129 — intervention group
Group type: COMPARATOR
Intervention: Pyrethrins and piperonyl butoxide (P/PB)
Number of subjects: 123
Study 18441041 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorimotor training programme using a sling suspension system
Number of subjects: 60
Study 18441041 — intervention group
Group type: COMPARATOR
Intervention: Routine physical therapy (Control)
Number of subjects: 60
Study 16401986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia by antegrade route (Group 1)
Number of subjects: 30
Study 16401986 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia by antegrade route (Group 2)
Number of subjects: 30
Study 16401986 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade/retrograde warm blood cardioplegia (Group 3)
Number of subjects: 30
Study 12556017 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml paper disposable cup
Number of subjects: 50
Study 12556017 — intervention group
Group type: COMPARATOR
Intervention: commercially produced spacer
Number of subjects: 50
Study 11022875 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin/mineral supplement
Number of subjects: 80
Study 11022875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8892717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled catheters
Number of subjects: 231
Study 8892717 — intervention group
Group type: COMPARATOR
Intervention: Nontunneled catheters (Control)
Number of subjects: 231
Study 1524967 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 12
Study 1524967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3158187 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 90 mg three times a day by mouth for 3 months after PTCA
Number of subjects: 92
Study 3158187 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists discontinued immediately after PTCA (Control)
Number of subjects: 92
Study 29996492 — intervention group
Group type: EXPERIMENTAL
Intervention: IF 1 (1.0 g protein/dL)
Number of subjects: 30
Study 29996492 — intervention group
Group type: EXPERIMENTAL
Intervention: IF 2 (1.3 g protein/dL)
Number of subjects: 30
Study 29996492 — intervention group
Group type: EXPERIMENTAL
Intervention: IF 3 (1.5 g protein/dL)
Number of subjects: 30
Study 29996492 — intervention group
Group type: COMPARATOR
Intervention: HM (exclusively breastfed)
Number of subjects: 30
Study 26201313 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly adalimumab
Number of subjects: 132
Study 26201313 — intervention group
Group type: EXPERIMENTAL
Intervention: Every other week adalimumab
Number of subjects: 132
Study 26201313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 26337327 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician feedback group (received feedback weekly)
Number of subjects: 299
Study 26337327 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive feedback)
Number of subjects: 299
Study 23099730 — intervention group
Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 171
Study 23099730 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 171
Study 20642454 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking (6 days/week for approx. 50 min/day for 8 weeks)
Number of subjects: 26
Study 20642454 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 26
Study 20642454 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 26
Study 18215618 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (substrates of ABCB1)
Number of subjects: 0
Study 16377916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nocturnal oxygen therapy (HOT group, n=25)
Number of subjects: 56
Study 16377916 — intervention group
Group type: COMPARATOR
Intervention: Usual breathing (control group, n=31)
Number of subjects: 56
Study 14651540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin (25 mg/kg per day)
Number of subjects: 72
Study 14651540 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (75-100 mg/kg per day)
Number of subjects: 72
Study 10985712 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve surgery (n = 43)
Number of subjects: 98
Study 10985712 — intervention group
Group type: COMPARATOR
Intervention: No mitral valve surgery (n = 51)
Number of subjects: 98
Study 10985712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort with severe mitral regurgitation (MR, n = 98)
Number of subjects: 98
Study 10985712 — intervention group
Group type: COMPARATOR
Intervention: Cohort with predominant left ventricular failure (LVF, n = 879)
Number of subjects: 98
Study 8972376 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen inhalation during surgery
Number of subjects: 31
Study 8972376 — intervention group
Group type: COMPARATOR
Intervention: Air inhalation during surgery
Number of subjects: 31
Study 1592575 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (a selective MAO-B inhibitor)
Number of subjects: 0